Pipeline

March 26, 2018

Company	Drug/Device	Medical Condition	Status
Avita Medical	RECELL	deep partial-thickness (second-degree) burns	Phase I trials initiated
Surface Oncology	SRF231	advanced solid tumors and hematologic malignancies	Phase I trials initiated
Cidara Therapeutics, Inc.	rezafungin acetate	candidemia and/or invasive candidiasis	Phase II trials initiated
Arena Pharmaceuticals, Inc.	etrasimod	ulcerative colitis	Phase II trials initiated
AMO Pharma	AMO-02 (tideglusib)	neuromuscular diseases	Phase II trials initiated
Cavion, Inc.	CX-8998	generalized epileptic syndromes	Phase IIa trials initiated
Antibe Therapeutics	ATB-346	gastric or duodenal ulcers of at least 3 mm diameter with unequivocal depth	Phase IIb trials initiated enrolling 244 subjects
Regeneron Pharmaceuticals, Inc.	EYLEA (aflibercept)	moderately severe to severe non-proliferative diabetic retinopathy	Phase III trials initiated
AstraZeneca	dapagliflozin	type 2 diabetes	Phase III trials initiated enrolling 321 subjects
Heron Therapeutics	HTX-011	Bunionectomy and hernia repair	Phase III trials initiated enrolling 412 subjects

Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Pipeline